Reverse transcriptase template switching during reverse transcriptase-polymerase chain reaction: Artificial generation of deletions in ribonucleotide reductase mRNA

Journal of Laboratory and Clinical Medicine

Volumn 137, Issue 6, 2001, Pages 422-428

  Mader, Robert M ^a   Schmidt, Wolfgang M ^a   Sedivy, Roland ^a   Rizovski, Blanka ^a   Braun, Johanna ^a   Kalipciyan, Maria ^a   Exner, Markus ^a   Steger, Guenther G ^a   Mueller, Manfred W ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

COLON CANCER; DNA TEMPLATE; GENE SWITCHING; GENETIC TRANSCRIPTION; LARGE SUBUNIT; MESSENGER RNA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RIBONUCLEOTIDE REDUCTASE; SIGNAL TRANSDUCTION; TAQ POLYMERASE;

EID: 0035370892     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1067/mlc.2001.115452     Document Type: Article

References (15)

1. Elledge SJ, Zhou Z, Ellen JB, Navas TA. DNA damage and cell cycle regulation of ribonucleotide reductase. Bioessays 1993;15:333-9.
2. Elledge SJ, Zhou Z, Ellen JB. Riboucleotide reductase: Regulation, regulation, regulation. TIBS 1992;17:119-23.
3. Eriksson S, Gräslund A, Skog S, Thelander L, Tribukait B. Cell-cycle dependent regulation of mammalian ribonucleotide reductase. J Biol Chem 1984;259:11695-700.
4. 1 in malignant H-ras transformed cell lines. J Biol Chem 1991;266:24097-100.
5. Choy BK, McClarty GA, Wright JA. Transient elevation of ribonucleotide reductase activity, M2 mRNA and M2 protein in BALB/c 3T3 fibroblasts in the presence of 12-O-tetradecanoylphorbol-13-acetate. Biochem Biophys Res Commun 1989;162:1417-24.
6. 1. J Cell Biochem 1995;57:543-56.
7. Baker CH, Bollinger JM, Stubbe J, Samono V, Robins MJ, Lippert B, et al. 2′-Deoxy-2′-methylenecytidine and 2′-deoxy-2′, 2′-difluorocytidine 5′-diphosphates: Potent mechanism-based inhibitors of ribonucleotide reductase. J Med Chem 1991;34:1879-84.
8. Bitonti AJ, Dumont JA, Bush TL, Cashman EA, Cross-Doersen DE, Wright PS, et al. Regression of human breast tumor xenografts in response to (E)-2′-deoxy-2′-(fluoromethylene)cytidine, an inhibitor of ribonucleoside diphosphate reductase. Cancer Res 1994;54:1485-90.
9. Carmichael J, Possinger K, Philip P, Beykirch M, Kerr H, Walling J, et al. Advanced breast cancer: A phase II trial with gemcitabine. J Clin Oncol 1995;13:2731-6.
10. Rubens RD, Kaye SB, Soukop M, Williams CJ, Brampton MH, Harris AL. Phase II trial of didox in advanced breast cancer. Br J Cancer 1991;64:1187-8.
11. Jensen RA, Page DL, Holt JT. Identification of genes expressed in premalignant breast disease by microscopy-directed cloning. Proc Natl Acad Sci USA 1994;91:9257-61.
12. Mader RM, Sieder AE, Braun J, Rizovski B, Kalipciyan M, Mueller MW, et al. Transcription and activity of 5-fluorouracil converting enzymes in fluoropyrimidine resistance in colon cancer in vitro. Biochem Pharmacol 1997;54: 1233-42.
13. Hultman T, Stahl S, Hornes E, Uhlen M. Direct solid phase sequencing of genomic and plasmid DNA using magnetic beads as solid support. Nucleic Acids Res 1989;17:4937-9.
14. Bowman RR, Hu WS, Pathak VK. Relative rates of retroviral reverse transcriptase template switching during RNA- and DNA-dependent synthesis. J Virol 1998;72:5198-206.
15. Delviks KA, Pathak VK. Effect of distance between homologous sequences and 3′ homology on the frequency of retroviral reverse transcriptase template switching. J Virol 1999; 73:7923-32.